Evidence map›Paper›PMID 37474260›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

Nitrogen Mustard-Induced Ex Vivo Human Cornea Injury Model and Therapeutic Intervention by Dexamethasone.

Neha Mishra, Rama Kant, Kushal Kandhari, David A Ammar, Neera Tewari-Singh, Mina B Pantcheva, J Mark Petrash, Chapla Agarwal, Rajesh Agarwal

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Neha MishraDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Rama KantDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Kushal KandhariDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
David A AmmarDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Neera Tewari-SinghDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Mina B PantchevaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
J Mark PetrashDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Chapla AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.).
Rajesh AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences (N.M., R.K., K.K., C.A., R.A.) and Department of Ophthalmology, School of Medicine (M.B.P., J.M.P.) University of Colorado-Anschutz Medical Campus, Aurora, Colorado; Lions Eye Institute for Transplant and Research, Tampa, Florida (D.A.A.); and Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan (N.T.-S.) rajesh.agarwal@cuanschutz.edu.ORCID https://orcid.org/0000-0002-9455-0235
University of Colorado Anschutz Medical Campus · US

Funding

Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.U01EY030405 · NEI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2020 to 2023
$2.9M
NEI NIH HHS U01 EY030405
6 · The paper itself

Abstract

Sulfur mustard (SM), a vesicating agent first used during World War I, remains a potent threat as a chemical weapon to cause intentional/accidental chemical emergencies. Eyes are extremely susceptible to SM toxicity. Nitrogen mustard (NM), a bifunctional alkylating agent and potent analog of SM, is used in laboratories to study mustard vesicant-induced ocular toxicity. Previously, we showed that SM-/NM-induced injuries (in vivo and ex vivo rabbit corneas) are reversed upon treatment with dexamethasone (DEX), a US Food and Drug Administration-approved, steroidal anti-inflammatory drug. Here, we optimized NM injuries in ex vivo human corneas and assessed DEX efficacy. For injury optimization, one cornea (randomly selected from paired eyes) was exposed to NM: 100 nmoles for 2 hours or 4 hours, and 200 nmoles for 2 hours, and the other cornea served as a control. Injuries were assessed 24 hours post NM-exposure. NM 100 nmoles exposure for 2 hours was found to cause optimal corneal injury (epithelial thinning [∼69%]; epithelial-stromal separation [6-fold increase]). In protein arrays studies, 24 proteins displayed ≥40% change in their expression in NM exposed corneas compared with controls. DEX administration initiated 2 hours post NM exposure and every 8 hours thereafter until 24 hours post-exposure reversed NM-induced corneal epithelial-stromal separation [2-fold decrease]). Of the 24 proteins dysregulated upon NM exposure, six proteins (delta-like canonical Notch ligand 1, FGFbasic, CD54, CCL7, endostatin, receptor tyrosine-protein kinase erbB-4) associated with angiogenesis, immune/inflammatory responses, and cell differentiation/proliferation, showed significant reversal upon DEX treatment (Student's

Indexed as

Chemical Warfare AgentsCorneal InjuriesMustard GasAnimalsCorneaDexamethasoneHumansIrritantsLigandsMechlorethamineRabbitsChemical Warfare AgentsDexamethasoneIrritantsLigandsMechlorethamineMustard Gas

Identifiers

PMID37474260
PMCPMC10801761
OpenAlexW4384924013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.